Smith D B, Rustin G J, Hitchins R, Bagshawe K D, Hoskins P
Cancer Research Campaign Department of Medical Oncology, Charing Cross Hospital, London, U.K.
Eur J Cancer Clin Oncol. 1988 Nov;24(11):1779-81. doi: 10.1016/0277-5379(88)90081-8.
The single agent activity of methotrexate in non-seminomatous germ cell tumours (NSGCT), and thus the rationale for its inclusion in combination regimens, has never been documented clearly. We have therefore reviewed all patients with NSGCT treated in this hospital from 1967 to 1970. Seventeen patients were identified who had a rising HCG excretion and who were treated with methotrexate alone as first line chemotherapy. Nine patients (53%) obtained a partial remission and a further seven patients a reduction in HCG production that was less than one log. Methotrexate is an active agent in testicular germ cell tumours and should be of particular value in treating CNS disease where intrathecal treatment may be required.
甲氨蝶呤在非精原细胞性生殖细胞肿瘤(NSGCT)中的单药活性,以及将其纳入联合治疗方案的理论依据,从未得到明确记录。因此,我们回顾了1967年至1970年在本院接受治疗的所有NSGCT患者。确定了17例HCG排泄升高且接受甲氨蝶呤单药作为一线化疗的患者。9例患者(53%)获得部分缓解,另有7例患者的HCG产生减少幅度小于1个对数。甲氨蝶呤是睾丸生殖细胞肿瘤的一种活性药物,在治疗可能需要鞘内治疗的中枢神经系统疾病中应具有特殊价值。